EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RB pathway and therapeutic sensitivity: new insights in breast cancer and Tamoxifen therapy



RB pathway and therapeutic sensitivity: new insights in breast cancer and Tamoxifen therapy



Cell Cycle 10(10): 1525-1525




(PDF emailed within 0-6 h: $19.90)

Accession: 055333545

Download citation: RISBibTeXText

PMID: 21502809

DOI: 10.4161/cc.10.10.15521



Related references

Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Research 72(19): 5048-5059, 2012

Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal-like breast cancer cells. Embo Molecular Medicine 5(5): 723-736, 2013

Radiation therapy plus tamoxifen versus tamoxifen alone after breast-conserving surgery in postmenopausal women with stage I breast cancer: a decision analysis. Journal of Clinical Oncology 21(12): 2260-2267, 2003

Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells. Biomedicine & PharmacoTherapy 77: 37-44, 2016

Therapeutic effect of tamoxifen versus combined tamoxifen and diethylstilboestrol in advanced breast cancer in postmenopausal women. European Journal of Cancer Suppl 1: 107-110, 1980

Therapeutic effect of tamoxifen alone versus tamoxifen in combination wtih gestagen and oestrogen in advanced breast cancer. Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres Dans les Recherches sur le Cancer 71: 169-177, 1980

Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women. Cancer Treatment Reports 63(2): 171-175, 1979

MiR-27b is epigenetically downregulated in tamoxifen resistant breast cancer cells due to promoter methylation and regulates tamoxifen sensitivity by targeting HMGB3. Biochemical and Biophysical Research Communications 477(4): 768-773, 2016

Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells. Plos One 9(9): E107369-E107369, 2015

Therapeutic effect of tamoxifen vs tamoxifen combined with medroxy progesterone acetate in advanced breast cancer in post menopausal women. Cancer Treatment Reports 63(2): 171-176, 1979

Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis. Clinical Cancer Research 16(4): 1264-1271, 2010

Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Research 66(12): 6370-6378, 2006

Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells. Breast Cancer Research 17(): 69-69, 2016

A comparative study among ftorafur, ftorafur plus tamoxifen, and tamoxifen in adjuvant therapy for breast cancer. The Chubu Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 20(15): 2325-2333, 1993

Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocrine-Related Cancer 18(5): 565-577, 2011